BACKGROUND & AIMS: Drug induced liver injury (DILI) is challenging because of the lack of biomarkers to predict mortality. Our aim was to describe miRNA changes in sera of subjects with acute idiosyncratic DILI and determine if levels of miRNAs were associated with 6 month mortality. METHODS: Clinical data and sera were collected from subjects enrolled in the Drug Induced Liver Injury Network prospective study. miRNAs were isolated from serum obtained from 78 subjects within 2 weeks of acute DILI and followed up for 6 months or longer. miRNAs were compared to 40 normal controls and 6 month survivors vs non-survivors. RESULTS: The mean age of the DILI cohort was 48 years, and 55% were female. Eleven (14.1%) subjects died, 10 within 6 months of DILI onset, 5 (45%) liver related. Lower levels of miRNAs-122, -4463 and -4270 were associated with death within 6 months (P<.05). None of the subjects with miRNA-122 greater than the median value died within 6 months for a sensitivity of 100% and specificity of 57%. In subjects with a serum albumin <2.8 g/dL and miR-122<7.89 RFU the sensitivity, specificity, positive and negative predictive values for death within 6 months were 100%, 57%, 38% and 100% respectively. CONCLUSIONS: Serum miRNA-122 combined with albumin accurately identified subjects who died within 6 months of drug induced liver injury. If confirmed prospectively, miRNA-122 and albumin may be useful in identifying patients at high risk for mortality or liver transplantation.
BACKGROUND & AIMS:Drug induced liver injury (DILI) is challenging because of the lack of biomarkers to predict mortality. Our aim was to describe miRNA changes in sera of subjects with acute idiosyncratic DILI and determine if levels of miRNAs were associated with 6 month mortality. METHODS: Clinical data and sera were collected from subjects enrolled in the Drug Induced Liver Injury Network prospective study. miRNAs were isolated from serum obtained from 78 subjects within 2 weeks of acute DILI and followed up for 6 months or longer. miRNAs were compared to 40 normal controls and 6 month survivors vs non-survivors. RESULTS: The mean age of the DILI cohort was 48 years, and 55% were female. Eleven (14.1%) subjects died, 10 within 6 months of DILI onset, 5 (45%) liver related. Lower levels of miRNAs-122, -4463 and -4270 were associated with death within 6 months (P<.05). None of the subjects with miRNA-122 greater than the median value died within 6 months for a sensitivity of 100% and specificity of 57%. In subjects with a serum albumin <2.8 g/dL and miR-122<7.89 RFU the sensitivity, specificity, positive and negative predictive values for death within 6 months were 100%, 57%, 38% and 100% respectively. CONCLUSIONS: Serum miRNA-122 combined with albumin accurately identified subjects who died within 6 months of drug induced liver injury. If confirmed prospectively, miRNA-122 and albumin may be useful in identifying patients at high risk for mortality or liver transplantation.
Authors: Guruprasad P Aithal; Lesley Ramsay; Ann K Daly; Nhareet Sonchit; Julian B S Leathart; Graeme Alexander; J Gerald Kenna; John Caldwell; Christopher P Day Journal: Hepatology Date: 2004-05 Impact factor: 17.425
Authors: Mercedes Robles-Diaz; M Isabel Lucena; Neil Kaplowitz; Camilla Stephens; Inmaculada Medina-Cáliz; Andres González-Jimenez; Eugenia Ulzurrun; Ana F Gonzalez; M Carmen Fernandez; Manuel Romero-Gómez; Miguel Jimenez-Perez; Miguel Bruguera; Martín Prieto; Fernando Bessone; Nelia Hernandez; Marco Arrese; Raúl J Andrade Journal: Gastroenterology Date: 2014-04-01 Impact factor: 22.682
Authors: Nury M Steuerwald; David M Foureau; H James Norton; Jie Zhou; Judith C Parsons; Naga Chalasani; Robert J Fontana; Paul B Watkins; William M Lee; K Rajender Reddy; Andrew Stolz; Jayant Talwalkar; Timothy Davern; Dhanonjoy Saha; Lauren N Bell; Huiman Barnhart; Jiezhun Gu; Jose Serrano; Herbert L Bonkovsky Journal: PLoS One Date: 2013-12-27 Impact factor: 3.240
Authors: Natalia Elfimova; Martin Schlattjan; Jan-Peter Sowa; Hans Peter Dienes; Ali Canbay; Margarete Odenthal Journal: Front Physiol Date: 2012-12-21 Impact factor: 4.566
Authors: Baqer A Haider; Alexander S Baras; Matthew N McCall; Joshua A Hertel; Toby C Cornish; Marc K Halushka Journal: PLoS One Date: 2014-02-26 Impact factor: 3.240
Authors: Robert James Hornby; Philip Starkey Lewis; James Dear; Chris Goldring; B Kevin Park Journal: Expert Rev Clin Pharmacol Date: 2014-04-02 Impact factor: 5.045
Authors: Rachel J Church; Gerd A Kullak-Ublick; Jiri Aubrecht; Herbert L Bonkovsky; Naga Chalasani; Robert J Fontana; Jens C Goepfert; Frances Hackman; Nicholas M P King; Simon Kirby; Patrick Kirby; John Marcinak; Sif Ormarsdottir; Shelli J Schomaker; Ina Schuppe-Koistinen; Francis Wolenski; Nadir Arber; Michael Merz; John-Michael Sauer; Raul J Andrade; Florian van Bömmel; Thierry Poynard; Paul B Watkins Journal: Hepatology Date: 2018-06-27 Impact factor: 17.425
Authors: Cynthia Ju; Meng Wang; Eunyoung Tak; Boyun Kim; Christoph Emontzpohl; Yang Yang; Xiaoyi Yuan; Huban Kutay; Yafen Liang; David R Hall; Wasim A Dar; J Steve Bynon; Peter Carmeliet; Kalpana Ghoshal; Holger K Eltzschig Journal: J Clin Invest Date: 2021-04-01 Impact factor: 14.808
Authors: Antonio Segovia-Zafra; Daniel E Di Zeo-Sánchez; Carlos López-Gómez; Zeus Pérez-Valdés; Eduardo García-Fuentes; Raúl J Andrade; M Isabel Lucena; Marina Villanueva-Paz Journal: Acta Pharm Sin B Date: 2021-11-18 Impact factor: 11.413